The 22E6 antibody is a novel option for targeting locally invading cells, potentially in combination with Cetuximab, and CD73 may serve as predictive marker for the response to Cetuximab treatment in advanced HNSCC patients. This evidence concerns the gene NT5E and head and neck squamous cell carcinoma.